SEC Filing Summary: Landec Corporation (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Landec Corporation on April 28, 2004, covering events occurring on April 27, 2004. The registrant is incorporated in California and operates from Menlo Park, California. Note: The input metadata references "LIFECORE BIOMEDICAL, INC.", but the filing text explicitly identifies the registrant as "LANDEC CORPORATION".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event regarding equity structure.
Material Changes
- Equity Conversion: The Company announced that all outstanding shares of Series B Preferred Stock will be converted into Common Stock.
- Effective Date: The conversion is scheduled to take place on May 7, 2004.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed in the text of this report, other than the structural change to the capitalization table resulting from the conversion.
Investor Verification Checklist
- Verify the exact number of Series B Preferred shares being converted to determine the dilution impact on existing common shareholders.
- Confirm the conversion ratio (shares of Common Stock received per share of Series B Preferred) as this is not explicitly stated in the summary text.
- Review the attached Exhibit 99.1 (Press Release) for additional details on the terms of the conversion.
- Check subsequent filings to confirm the conversion was executed on the scheduled date of May 7, 2004.